Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please find the link for the transcript of the Q1 FY24 Earnings Call conducted on July 27, 2023 and uploaded on website of the Company on July 31, 2023. Syngene International Ltd - 539268 - Voting Results Under Regulation 44(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Voting Results under Regulation 44(3) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. Syngene International Ltd - 539268 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
The Consolidated Scrutinizer''s Report on the remote e-voting and voting through Insta-poll 30th AGM on July 26, 2023. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of SEBI (LODR) Regulations,2015 please find attached the copy of newspaper publication of the financial results in Financial Express and Vijayvani published on 27th July,2023 Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI(LODR) Regulations,2015, please find the link for the audio recording of the Q1 FY2024 earnings call conducted on July 27, 2023
Syngene International Results Earnings Call for Q1FY24
Conference Call with Syngene International Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.
Syngene International gains 6% on healthy Q1 numbers
The firm's consolidated profit was up 26 percent year-on-year increase at Rs 93 crore, while revenue from operations rose 25.4 percent to Rs 808.1 crore in the June quarter Syngene International Ltd - 539268 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 30th Annual General Meeting. Q1FY24 Quarterly Result Announced for Syngene International Ltd.
Pharmaceuticals company Syngene International announced Q1FY24 results: Acquisition of biologics manufacturing facility in Bangalore to complete by the end of Q3FY24. US FDA approval for API manufacturing plant in Mangalore received. Acquisition of land in Hyderabad to support long-term growth in research services Q1FY24 revenue was up 26% YoY to Rs 832 crore Profit after tax for the quarter increased 26% YoY to Rs 93 crore. Commenting on the first quarter, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International, said, “First quarter performance was strong, led by Development and Manufacturing Services and well supported by our research divisions: Discovery Services and the Dedicated Centers. Earlier this month we announced our intention to acquire a site offering additional biologics manufacturing capacity close to our existing Bangalore campus. With 20,000 liters of installed biologics capacity - and scope for further expansion – the site strengthens our position as a leading biologics contract development and manufacturing service provider. Also during the quarter, we were pleased to receive US FDA approval for our API facility in Mangalore. This approval reflects the robust quality standards applied in all our operations and represents an important building block for our small molecule commercial manufacturing strategy. Finally, we completed the acquisition of development land in Hyderabad to support the long-term growth ambitions of our Research Services division. Together, these actions show meaningful progress on our strategy to become a global leader in both research services (CRO) and manufacturing services (CDMO) and give us the capacity we need for the next stage of growth.” Sibaji Biswas, Chief Financial Officer, Syngene International added, “We are pleased to report a solid start to the year. The financial performance is in line with the revenue growth guidance for the year on a constant currency basis. At 25%, EBITDA growth reflects better operating leverage as we gain scale in development and manufacturing services. We made investments in growing our portfolios in biologics manufacturing and discovery services. Despite these investments, the Company will continue to maintain a strong balance sheet and a low debt profile.” Result PDF Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter ended June 30, 2023.